[S02DA03, antipyrine, The metabolism of Ozanimod can be decreased when combined with Antipyrine.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ozanimod.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Ozanimod.]
[L04AA27, fingolimod, Ozanimod may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The metabolism of Ozanimod can be decreased when combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Ozanimod.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ozanimod.]
[L02BA01, tamoxifen, The metabolism of Ozanimod can be decreased when combined with Tamoxifen.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Ozanimod.]
[N04BC07, apomorphine, The metabolism of Ozanimod can be decreased when combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Ozanimod.]
[R03DA04, theophylline, The metabolism of Ozanimod can be decreased when combined with Theophylline.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Eribulin is combined with Ozanimod.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Thiotepa is combined with Ozanimod.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Ozanimod.]
[B01AC05, ticlopidine, The metabolism of Ozanimod can be decreased when combined with Ticlopidine.]
[V04CA01, tolbutamide, The metabolism of Ozanimod can be decreased when combined with Tolbutamide.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Ozanimod.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ozanimod.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Ozanimod.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Ozanimod is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Ozanimod.]
[N03AC02, trimethadione, The metabolism of Ozanimod can be decreased when combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Ozanimod can be decreased when combined with Trimethoprim.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Ozanimod.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Ozanimod.]
[L01EX04, vandetanib, Vandetanib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Ozanimod can be decreased when combined with Abiraterone.]
[J05AG05, rilpivirine, Rilpivirine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Belatacept is combined with Ozanimod.]
[C08DA01, verapamil, The metabolism of Ozanimod can be decreased when combined with Verapamil.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Ozanimod.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Ozanimod.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Ozanimod.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Ozanimod.]
[L01EC01, vemurafenib, Vemurafenib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ozanimod.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ozanimod.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Ozanimod.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ozanimod.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Ozanimod.]
[L01XJ01, vismodegib, Vismodegib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Ozanimod is combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Ozanimod.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Ozanimod.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ozanimod.]
[G04BE10, avanafil, Avanafil may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Ozanimod.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ozanimod.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Carfilzomib is combined with Ozanimod.]
[V03AX03, cobicistat, Cobicistat may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L02BB04, enzalutamide, The metabolism of Ozanimod can be decreased when combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Bosutinib is combined with Ozanimod.]
[L04AA31, teriflunomide, Teriflunomide may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Abetimus is combined with Ozanimod.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Ozanimod.]
[L01EX05, regorafenib, Regorafenib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J05AE04, nelfinavir, Nelfinavir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Bendamustine is combined with Ozanimod.]
[L04AA29, tofacitinib, Ozanimod may increase the immunosuppressive activities of Tofacitinib.]
[L01EX07, cabozantinib, The metabolism of Ozanimod can be decreased when combined with Cabozantinib.]
[L01EA05, ponatinib, Ponatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[B01AF02, apixaban, The metabolism of Ozanimod can be decreased when combined with Apixaban.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pomalidomide is combined with Ozanimod.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Ozanimod.]
[A06AX06, tegaserod, The metabolism of Ozanimod can be decreased when combined with Tegaserod.]
[M01AH01, celecoxib, The metabolism of Ozanimod can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Everolimus is combined with Ozanimod.]
[L01EC02, dabrafenib, The metabolism of Ozanimod can be decreased when combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Ozanimod can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The metabolism of Ozanimod can be decreased when combined with Benzyl alcohol.]
[L01EB03, afatinib, Afatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N06AX28, levomilnacipran, The metabolism of Ozanimod can be decreased when combined with Levomilnacipran.]
[C02KX05, riociguat, The metabolism of Ozanimod can be decreased when combined with Riociguat.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Ibrutinib is combined with Ozanimod.]
[N06AX26, vortioxetine, The metabolism of Ozanimod can be decreased when combined with Vortioxetine.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Apremilast is combined with Ozanimod.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Ozanimod.]
[C10AB02, bezafibrate, The metabolism of Ozanimod can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Ozanimod.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Ozanimod.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Belinostat is combined with Ozanimod.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Idelalisib is combined with Ozanimod.]
[N07XX08, tafamidis, Tafamidis may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[R03AC19, olodaterol, The metabolism of Ozanimod can be decreased when combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Ozanimod.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Decitabine is combined with Ozanimod.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ozanimod.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Ozanimod.]
[J05AP09, dasabuvir, Dasabuvir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Olaparib is combined with Ozanimod.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Ozanimod.]
[L01EF01, palbociclib, Palbociclib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Panobinostat is combined with Ozanimod.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Ozanimod.]
[A04AD14, rolapitant, Rolapitant may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[A02BC03, lansoprazole, Lansoprazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Trabectedin is combined with Ozanimod.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Ozanimod.]
[J02AC05, isavuconazole, Isavuconazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EB04, osimertinib, Osimertinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01ED03, alectinib, Alectinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[B01AC27, selexipag, The metabolism of Ozanimod can be decreased when combined with Selexipag.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Ozanimod.]
[L01XX52, venetoclax, Venetoclax may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N07BC01, buprenorphine, Buprenorphine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Ozanimod.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ozanimod.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[S01GX07, azelastine, The metabolism of Ozanimod can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, Rucaparib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Ozanimod.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Ozanimod.]
[N06BC01, caffeine, Caffeine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Ozanimod.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Ozanimod.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Ozanimod.]
[L01ED04, brigatinib, Brigatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Ozanimod.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Ozanimod.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Ozanimod.]
[L01XX59, enasidenib, Enasidenib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Vorinostat is combined with Ozanimod.]
[L01EF03, abemaciclib, Abemaciclib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J05AG03, efavirenz, The metabolism of Ozanimod can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Ozanimod.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ozanimod.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Ozanimod.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L02BB05, apalutamide, The metabolism of Ozanimod can be decreased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ozanimod.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ozanimod.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N03AX24, cannabidiol, Cannabidiol may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Baricitinib is combined with Ozanimod.]
[H01CC03, elagolix, The metabolism of Ozanimod can be decreased when combined with Elagolix.]
[N03AX17, stiripentol, Stiripentol may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Ozanimod can be increased when combined with Tecovirimat.]
[L01EB07, dacomitinib, Dacomitinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Ozanimod.]
[L01EX13, gilteritinib, Gilteritinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XJ03, glasdegib, Glasdegib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Ozanimod.]
[P02BX04, triclabendazole, The metabolism of Ozanimod can be decreased when combined with Triclabendazole.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Siponimod is combined with Ozanimod.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Ozanimod is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Ozanimod can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Ozanimod.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Ozanimod is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Ozanimod can be decreased when combined with Alpelisib.]
[L02BB06, darolutamide, Darolutamide may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Ozanimod is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N04CX01, istradefylline, Istradefylline may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Deflazacort is combined with Ozanimod.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Ozanimod.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ozanimod.]
[N02CC08, lasmiditan, Lasmiditan may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Ozanimod is combined with Diroximel fumarate.]
[N03AX25, cenobamate, The metabolism of Ozanimod can be increased when combined with Cenobamate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Teprotumumab is combined with Ozanimod.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Ozanimod.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The metabolism of Ozanimod can be decreased when combined with Selumetinib.]
[M01AH02, rofecoxib, The metabolism of Ozanimod can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Ozanimod.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ozanimod.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ozanimod.]
[L01EH03, tucatinib, The metabolism of Ozanimod can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, Capmatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ozanimod.]
[L01EX19, ripretinib, Ripretinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Ozanimod can be increased when it is combined with Selpercatinib.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Ozanimod is combined with Inebilizumab.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Stepronin is combined with Ozanimod.]
[J05AX29, fostemsavir, Fostemsavir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC19, satralizumab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Satralizumab.]
[P01BA01, chloroquine, The metabolism of Ozanimod can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Ozanimod.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Voclosporin is combined with Ozanimod.]
[L01EX21, tepotinib, Tepotinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Ozanimod.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Ozanimod.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Ponesimod is combined with Ozanimod.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ozanimod.]
[A02BA01, cimetidine, The metabolism of Ozanimod can be decreased when combined with Cimetidine.]
[L01XX73, sotorasib, The serum concentration of Ozanimod can be increased when it is combined with Sotorasib.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Ozanimod.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Ozanimod is combined with Pegcetacoplan.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Ozanimod.]
[L04AA48, belumosudil, Belumosudil may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Ozanimod.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Ozanimod is combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, Clofazimine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[B06AX04, mitapivat, The metabolism of Ozanimod can be increased when combined with Mitapivat.]
[L01EJ03, pacritinib, Pacritinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[J02AC06, oteseconazole, Oteseconazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Ozanimod is combined with Deucravacitinib.]
[H01CC04, linzagolix, The serum concentration of Ozanimod can be increased when it is combined with Linzagolix.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Ozanimod is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Nelarabine is combined with Ozanimod.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Ozanimod.]
[N02CC05, almotriptan, The metabolism of Ozanimod can be decreased when combined with Almotriptan.]
[J02AC02, itraconazole, Itraconazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EA01, imatinib, Imatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[R06AX13, loratadine, The metabolism of Ozanimod can be decreased when combined with Loratadine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Meprednisone is combined with Ozanimod.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Ozanimod.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ozanimod.]
[S01XA18, cyclosporine, Ozanimod may increase the immunosuppressive activities of Cyclosporine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Ozanimod.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ozanimod.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ozanimod.]
[J04BA02, dapsone, The metabolism of Ozanimod can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ozanimod.]
[L02BB02, nilutamide, The metabolism of Ozanimod can be decreased when combined with Nilutamide.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ozanimod.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Ozanimod.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ozanimod.]
[S03BA01, dexamethasone, Dexamethasone may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[G04BD04, oxybutynin, The metabolism of Ozanimod can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Ozanimod.]
[L01EB01, gefitinib, Gefitinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N03AC01, paramethadione, The metabolism of Ozanimod can be decreased when combined with Paramethadione.]
[B01AC04, clopidogrel, The metabolism of Ozanimod can be decreased when combined with Clopidogrel.]
[S01BC03, diclofenac, The metabolism of Ozanimod can be decreased when combined with Diclofenac.]
[A10BG03, pioglitazone, The metabolism of Ozanimod can be decreased when combined with Pioglitazone.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Ixabepilone is combined with Ozanimod.]
[L01EB02, erlotinib, The metabolism of Ozanimod can be decreased when combined with Erlotinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Pirarubicin is combined with Ozanimod.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Ozanimod.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ozanimod.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ozanimod.]
[J05AE08, atazanavir, The metabolism of Ozanimod can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Ozanimod can be decreased when combined with Treprostinil.]
[C08DB01, diltiazem, The metabolism of Ozanimod can be decreased when combined with Diltiazem.]
[A03FA02, cisapride, The metabolism of Ozanimod can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Ozanimod.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Ozanimod is combined with Natalizumab.]
[S02AA12, rifamycin SV, The metabolism of Ozanimod can be decreased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Ozanimod can be increased when combined with Rifapentine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Ozanimod.]
[L01EX01, sunitinib, Sunitinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Ozanimod.]
[S01BC05, ketorolac, The metabolism of Ozanimod can be decreased when combined with Ketorolac.]
[R03AC12, salmeterol, The metabolism of Ozanimod can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Ozanimod can be decreased when combined with Domperidone.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Ozanimod.]
[C10AA01, simvastatin, The metabolism of Ozanimod can be decreased when combined with Simvastatin.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Ozanimod.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Ozanimod.]
[D01BA02, terbinafine, The metabolism of Ozanimod can be decreased when combined with Terbinafine.]
[C03CA04, torsemide, The metabolism of Ozanimod can be decreased when combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Ozanimod.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Ozanimod is combined with Trofosfamide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ozanimod.]
[N06AX16, venlafaxine, Venlafaxine may increase the excretion rate of Ozanimod which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Ozanimod.]
[N05CF01, zopiclone, The metabolism of Ozanimod can be decreased when combined with Zopiclone.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Ozanimod.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Ozanimod.]
[G03CC04, estrone, Estrone may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The metabolism of Ozanimod can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Ozanimod can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Ozanimod can be decreased when combined with Fluvastatin.]
[L02AA03, ethinyl estradiol, The metabolism of Ozanimod can be decreased when combined with Ethinylestradiol.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Ozanimod.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Ozanimod.]
[R06AX12, terfenadine, The metabolism of Ozanimod can be decreased when combined with Terfenadine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Ozanimod.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ozanimod.]
[C08CA02, felodipine, The metabolism of Ozanimod can be decreased when combined with Felodipine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Ozanimod.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Ozanimod.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Ozanimod.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ozanimod.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Ozanimod.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Ozanimod.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Ozanimod.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Ozanimod.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Ozanimod.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Ozanimod.]
[N05CF04, eszopiclone, The metabolism of Ozanimod can be decreased when combined with Eszopiclone.]
[C10AB04, gemfibrozil, The metabolism of Ozanimod can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, Dasatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EH01, lapatinib, The metabolism of Ozanimod can be decreased when combined with Lapatinib.]
[L01EX02, sorafenib, The metabolism of Ozanimod can be decreased when combined with Sorafenib.]
[P01BX01, halofantrine, The metabolism of Ozanimod can be decreased when combined with Halofantrine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Ozanimod.]
[C09CA01, losartan, The metabolism of Ozanimod can be decreased when combined with Losartan.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Ozanimod.]
[C08CA10, nilvadipine, The metabolism of Ozanimod can be decreased when combined with Nilvadipine.]
[S02BA01, hydrocortisone, The metabolism of Ozanimod can be increased when combined with Hydrocortisone.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Ozanimod.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ozanimod.]
[J04AB04, rifabutin, The metabolism of Ozanimod can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ozanimod can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Ozanimod.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Ozanimod.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Ozanimod.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Ozanimod.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Ozanimod.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Ozanimod.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ozanimod.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ozanimod.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Ozanimod.]
[A10BH01, sitagliptin, The metabolism of Ozanimod can be decreased when combined with Sitagliptin.]
[C10AA06, cerivastatin, The metabolism of Ozanimod can be decreased when combined with Cerivastatin.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ozanimod.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Ozanimod.]
[N01AX03, ketamine, The metabolism of Ozanimod can be decreased when combined with Ketamine.]
[J02AB02, ketoconazole, The metabolism of Ozanimod can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Ozanimod can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The metabolism of Ozanimod can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Ozanimod can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Abatacept is combined with Ozanimod.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Ozanimod.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Lomustine is combined with Ozanimod.]
[A07DA03, loperamide, The metabolism of Ozanimod can be decreased when combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Ozanimod can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Temsirolimus is combined with Ozanimod.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Pralatrexate is combined with Ozanimod.]
[L01EA03, nilotinib, Nilotinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ozanimod.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Ozanimod.]
[N03AB04, mephenytoin, The metabolism of Ozanimod can be decreased when combined with Mephenytoin.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Ozanimod.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ozanimod.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Ozanimod.]
[V04CG05, methylene blue, The metabolism of Ozanimod can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ozanimod.]
[P01AB01, metronidazole, The metabolism of Ozanimod can be decreased when combined with Metronidazole.]
[S02AA13, miconazole, The metabolism of Ozanimod can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Ozanimod can be decreased when combined with Aminophenazone.]
[G03XB01, mifepristone, The serum concentration of Ozanimod can be increased when it is combined with Mifepristone.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Ozanimod.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ozanimod.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Ozanimod.]
[N06AA09, amitriptyline, The metabolism of Ozanimod can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Ozanimod can be decreased when combined with Morphine.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Ozanimod.]
[B02BX05, eltrombopag, Eltrombopag may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Ozanimod.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Ozanimod.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ozanimod.]
[P01BA06, amodiaquine, The metabolism of Ozanimod can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Ozanimod can be decreased when combined with Raloxifene.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Ozanimod.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ozanimod.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Ozanimod.]
[M02AA12, naproxen, The metabolism of Ozanimod can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Ozanimod can be decreased when combined with Troglitazone.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Docetaxel is combined with Ozanimod.]
[A10BX02, repaglinide, The metabolism of Ozanimod can be decreased when combined with Repaglinide.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[M04AA03, febuxostat, Febuxostat may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Ozanimod.]
[C08CA04, nicardipine, The metabolism of Ozanimod can be decreased when combined with Nicardipine.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Rilonacept is combined with Ozanimod.]
[A02BC01, omeprazole, Omeprazole may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Ozanimod.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Ozanimod.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ozanimod.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ozanimod.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Ozanimod.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Ozanimod.]
[N03AA02, phenobarbital, The metabolism of Ozanimod can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Ozanimod.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Ozanimod.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Ozanimod.]
[C10AA05, atorvastatin, The metabolism of Ozanimod can be decreased when combined with Atorvastatin.]
[J05AE01, saquinavir, Saquinavir may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[S01BC06, piroxicam, The metabolism of Ozanimod can be decreased when combined with Piroxicam.]
[C09CA04, irbesartan, The metabolism of Ozanimod can be decreased when combined with Irbesartan.]
[D05AX05, tazarotene, The metabolism of Ozanimod can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Ozanimod can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Ozanimod can be decreased when combined with Anastrozole.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Ozanimod.]
[J05AE03, ritonavir, The metabolism of Ozanimod can be decreased when combined with Ritonavir.]
[C10AA08, pitavastatin, The metabolism of Ozanimod can be decreased when combined with Pitavastatin.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Ozanimod.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Ozanimod.]
[M04AB01, probenecid, The metabolism of Ozanimod can be increased when combined with Probenecid.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Ozanimod.]
[C10AB05, fenofibrate, The metabolism of Ozanimod can be decreased when combined with Fenofibrate.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N01AX10, propofol, The metabolism of Ozanimod can be decreased when combined with Propofol.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ozanimod.]
[R03DC03, montelukast, The metabolism of Ozanimod can be decreased when combined with Montelukast.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Ozanimod.]
[P01BD01, pyrimethamine, The metabolism of Ozanimod can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Ozanimod can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Ozanimod can be decreased when combined with Quinine.]
[J04AB02, rifampin, The metabolism of Ozanimod can be increased when combined with Rifampicin.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N05CA06, secobarbital, The metabolism of Ozanimod can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Ozanimod can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ozanimod.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Ozanimod.]
[L01CD04, cabazitaxel, Cabazitaxel may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ozanimod.]
[C03DA01, spironolactone, The metabolism of Ozanimod can be decreased when combined with Spironolactone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Ozanimod is combined with Hydrocortisone butyrate.]
